Pitfalls in Oncogeriatrics
- PMID: 37296871
- PMCID: PMC10251873
- DOI: 10.3390/cancers15112910
Pitfalls in Oncogeriatrics
Abstract
An oncogeriatric interdisciplinary activity exists only in a minority of high-income countries, and it is almost absent in those with lower incomes. Considering topics, sessions, and tracks in the main meetings and conferences of the major Oncological Societies in Europe and worldwide, the USA excluded, little attention has thus far been paid to the problem of cancer in the elderly. Again, with the exception of the USA, the major cooperative groups, for example, the EORTC in Europe, have only dedicated marginal attention to the research of cancer in the elderly. Despite major shortcomings, professionals interested in geriatric oncology have taken a number of important initiatives to highlight the benefits of this particular activity, including the organization of an international society (Société Internationale de Oncogeriatrie, or SIOG). In spite of these efforts, the authors believe that the management of cancer in the older population is still encountering several important and generalized pitfalls. The main obstacle is the grossly inadequate number of geriatricians and clinical oncologists necessary to an integrated care of the ever-expanding aging population, but other hurdles have been reported. Additionally, the prejudice of ageism can lead to missing potential resources for the development of a generalized oncogeriatric approach.
Keywords: cancer in the elderly; geriatric oncology; oncogeriatrics.
Conflict of interest statement
Silvio Monfardini has received, in the year 2022, an honorarium to act as Chairman of the project of the European School of Oncology on the History of European Clinical Oncology. Francesco Perrone received institutional financial support for clinical trials promoted by the National Cancer Institute of Naples from Roche, Bayer, AstraZeneca, Pfizer, Incyte, GSK (Tesaro), and Merck and personal honoraria from Bayer, Pierre Fabre, AstraZeneca, Incyte, Ipsen, Clovis, Astellas, Sanofi, Roche, and Pfizer. Lodovico Balducci has nothing to declare.
References
-
- Kunkler I.H., Audisio R., Belkacemi Y., Betz M., Gore E., Hoffe S., Kirova Y., Koper P., Lagrange J.L., Markouizou A., et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: The International Society of Geriatric Oncology (SIOG) task force. Ann. Oncol. 2014;25:2134–2146. doi: 10.1093/annonc/mdu104. - DOI - PubMed
-
- Mohile S.G., Dale W., Somerfield M.R., Schonberg M.A., Boyd C.M., Burhenn P.S., Canin B., Cohen H.J., Holmes H.M., Hopkins J.O., et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J. Clin. Oncol. 2018;36:2326–2347. doi: 10.1200/JCO.2018.78.8687. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources